PURPOSE: To analyze the cycle outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS), when oocyte maturation was triggered by gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation. METHODS: One hundred twenty-nine women aged ≤ 45 years, diagnosed with stage ≤ 3 breast cancer, with normal ovarian reserve who desired fertility preservation were included in the retrospective cohort study. Ovarian stimulation was achieved utilizing letrozole and gonadotropins. Oocyte maturation was triggered with GnRHa or hCG. Baseline AMH levels, number of oocytes, maturation and fertilization rates, number of embryos, and the incidence of OHSS was recorded. RESULTS: The serum AMH levels were similar between GnRHa and hCG groups (2.7 ± 1.9 vs. 2.1 ± 1.8; p = 0.327). There was one case of mild or moderate OHSS in the GnRHa group compared to 12 in the hCG group (2.1 % vs. 14.4 %, p = 0.032). The maturation and fertilization rates, and the number of cryopreserved embryos were significantly higher in the GnRHa group. CONCLUSIONS: GnRHa trigger improved cycle outcomes as evidenced by the number of mature oocytes and cryopreserved embryos, while significantly reducing the risk of OHSS in breast cancer patients undergoing fertility preservation.
PURPOSE: To analyze the cycle outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS), when oocyte maturation was triggered by gonadotropin-releasing hormone agonist (GnRHa) versus humanchorionic gonadotropin (hCG) in breast cancerpatients undergoing fertility preservation. METHODS: One hundred twenty-nine women aged ≤ 45 years, diagnosed with stage ≤ 3 breast cancer, with normal ovarian reserve who desired fertility preservation were included in the retrospective cohort study. Ovarian stimulation was achieved utilizing letrozole and gonadotropins. Oocyte maturation was triggered with GnRHa or hCG. Baseline AMH levels, number of oocytes, maturation and fertilization rates, number of embryos, and the incidence of OHSS was recorded. RESULTS: The serum AMH levels were similar between GnRHa and hCG groups (2.7 ± 1.9 vs. 2.1 ± 1.8; p = 0.327). There was one case of mild or moderate OHSS in the GnRHa group compared to 12 in the hCG group (2.1 % vs. 14.4 %, p = 0.032). The maturation and fertilization rates, and the number of cryopreserved embryos were significantly higher in the GnRHa group. CONCLUSIONS: GnRHa trigger improved cycle outcomes as evidenced by the number of mature oocytes and cryopreserved embryos, while significantly reducing the risk of OHSS in breast cancerpatients undergoing fertility preservation.
Authors: Mohamed Afm Youssef; Fulco Van der Veen; Hesham G Al-Inany; Georg Griesinger; Monique H Mochtar; Ismail Aboulfoutouh; Sherif M Khattab; Madelon van Wely Journal: Cochrane Database Syst Rev Date: 2011-01-19
Authors: Daniel Bodri; Juan José Guillén; Anna Galindo; Daniel Mataró; Aïda Pujol; Oriol Coll Journal: Fertil Steril Date: 2008-03-25 Impact factor: 7.329
Authors: Kathryn Coyne; MacKenzie Purdy; Kathleen O'Leary; Jerome L Yaklic; Steven R Lindheim; Leslie A Appiah Journal: Front Public Health Date: 2014-12-05
Authors: Hady El Hachem; Charlotte Sonigo; Julie Benard; Marion Presse; Christophe Sifer; Nathalie Sermondade; Michael Grynberg Journal: PLoS One Date: 2018-12-06 Impact factor: 3.240
Authors: Anna Marklund; Sandra Eloranta; Ida Wikander; Margareta Laczna Kitlinski; Mikael Lood; Elizabeth Nedstrand; Ann Thurin-Kjellberg; Pu Zhang; Jonas Bergh; Kenny A Rodriguez-Wallberg Journal: Hum Reprod Date: 2020-04-28 Impact factor: 6.918